Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
|Videos|June 2, 2021
Study explores urology appointment no-shows
Author(s)Urology Times staff
“We had a very low rate of nonattendance amongst oncology appointments, as compared to some other appointments,” says Randie White, MD.
Advertisement
In this interview, Randie White, MD, discusses findings from the recent Urology Practice study, “Failure to Attend Urology Appointments: A Retrospective Analysis of a Single Urban Academic Practice,” for which she served as study author. White is a urology resident at Maine Medical Center, Portland.
Advertisement
Related to this article
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Tamim Niazi, MDCM, reviews darolutamide data from DASL-HiCaP
2
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
3
FDA updates in urology: October 2026
4
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
5